Xoft microTube Inc.'s micro-miniature flexible x-ray tubes are designed to conform to any body cavity and deliver very high doses of radiation. For the company's lead indication, breast cancer, Xoft's goal is to provide single fraction radiation therapy delivered to the surgical margins after tumor resection in just one 30-minute treatment.

Having built up a $500 million business with the only approved coronary stent on the US market, Johnson & Johnson's Cordis watched virtually all of it slip away to competitors who came to market with superior products. But now the company is back, with the introduction of a new line of stents, expansion into a broad line of cardio- and vascular products, and a head start in one of the most promising device areas: drug-coated stents. Cordis' goal: to be number one again.